DEA
REGN icon

DoubleLine ETF Adviser’s Regeneron Pharmaceuticals REGN Stock Holding History

DoubleLine ETF Adviser’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.02M Buy
+1,316
New +$1.01M 0.39% 68

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

DoubleLine ETF Adviser's REGN Position: Q1 2026 in Review

DoubleLine ETF Adviser opened a new position in Regeneron Pharmaceuticals (REGN) in Q1 2026: 1,316 shares worth $1.02M. The stake represents 0.39% of the portfolio and ranks #68 among its holdings.

1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • DoubleLine ETF Adviser held 1,316 shares of Regeneron Pharmaceuticals worth $1.02M as of Q1 2026.
  • Regeneron Pharmaceuticals was a new DoubleLine ETF Adviser position in Q1 2026.
  • Regeneron Pharmaceuticals made up 0.39% of DoubleLine ETF Adviser's portfolio in Q1 2026, its #68 holding.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on DoubleLine ETF Adviser's 13F filing for Q1 2026, filed 15 May 2026.